Clinical Trial Diversity Action Plan Waivers Will Be ‘Very Rare,’ US FDA Official Says

 
• By Nielsen Hobbs
  
Hundreds of diverse headshots
Sponsors should be prepared to check all the boxes on diversity action plans and not anticipate a waiver. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Diversity & Inclusion

More from Clinical Trials